|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
GB2353887B
(en)
|
1999-09-04 |
2003-09-24 |
Ibm |
Speech recognition system
|
|
WO2003028809A1
(en)
*
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Methods of therapy for b-cell malignancies
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
CA2544951A1
(en)
*
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
|
|
PT1694360E
(pt)
*
|
2003-11-04 |
2010-12-13 |
Novartis Vaccines & Diagnostic |
Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
|
|
ATE474598T1
(de)
*
|
2003-11-04 |
2010-08-15 |
Novartis Vaccines & Diagnostic |
Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
CN101014386A
(zh)
*
|
2004-04-27 |
2007-08-08 |
诺华疫苗和诊断公司 |
拮抗性抗－cd40单克隆抗体及其使用方法
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
US20080057070A1
(en)
*
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
US20150315284A1
(en)
|
2004-11-09 |
2015-11-05 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
EP1888098A2
(en)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
|
KR20080073293A
(ko)
|
2005-10-14 |
2008-08-08 |
메디뮨 엘엘씨 |
항체 라이브러리의 세포 디스플레이
|
|
EP2125893A2
(en)
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
AU2008247819B2
(en)
|
2007-05-01 |
2013-02-14 |
Research Development Foundation |
Immunoglobulin Fc libraries
|
|
ES2572356T3
(es)
|
2007-11-09 |
2016-05-31 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
|
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
BR112012024713B1
(pt)
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpo humanizado, seus usos e composição farmacêutica que o compreende
|
|
WO2012046745A1
(ja)
|
2010-10-04 |
2012-04-12 |
独立行政法人理化学研究所 |
Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
US9409950B2
(en)
|
2010-12-23 |
2016-08-09 |
Biogen Ma Inc. |
Linker peptides and polypeptides comprising same
|
|
BR112013026828A2
(pt)
|
2011-04-21 |
2016-11-29 |
Bristol Myers Squibb Co |
polipeptídeos de anticorpo que antagonizam cd40
|
|
CN113461819B
(zh)
|
2011-04-29 |
2024-01-02 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
EP3680251A1
(en)
|
2011-09-30 |
2020-07-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules for promoting elimination of antigens
|
|
JP6226752B2
(ja)
|
2012-02-09 |
2017-11-08 |
中外製薬株式会社 |
抗体のＦｃ領域改変体
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
TW202237660A
(zh)
|
2012-08-24 |
2022-10-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
AU2013337903B2
(en)
*
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
US20140294812A1
(en)
|
2013-03-15 |
2014-10-02 |
Xencor, Inc. |
Fc variants that improve fcrn binding and/or increase antibody half-life
|
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
|
GB201308658D0
(en)
|
2013-05-14 |
2013-06-26 |
Isis Innovation |
Antibodies
|
|
WO2015134988A1
(en)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
KR20170035945A
(ko)
*
|
2014-08-14 |
2017-03-31 |
에프. 호프만-라 로슈 아게 |
인간 cd40을 활성화시키는 항체 및 인간 pd-l1에 대한 항체의 병용 요법
|
|
US20170233485A1
(en)
*
|
2014-08-18 |
2017-08-17 |
Biogen Ma Inc. |
Anti-cd40 antibodies and uses thereof
|
|
MY189836A
(en)
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
|
TN2017000440A1
(en)
|
2015-04-17 |
2019-04-12 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
US10174121B2
(en)
|
2015-05-29 |
2019-01-08 |
Abbvie, Inc. |
Anti-CD40 antibodies
|
|
HK1252666A1
(zh)
*
|
2015-06-29 |
2019-05-31 |
Bristol-Myers Squibb Company |
针对cd40的抗体
|
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
CR20180177A
(es)
|
2015-09-30 |
2018-06-22 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
|
|
JP7471819B2
(ja)
|
2016-10-06 |
2024-04-22 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
工程不純物への結合が低下している抗体
|
|
KR102715540B1
(ko)
|
2017-03-14 |
2024-10-08 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
US20200095323A1
(en)
|
2017-03-20 |
2020-03-26 |
The General Hospital Corporation |
MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
|
|
KR20200012907A
(ko)
|
2017-05-25 |
2020-02-05 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
|
|
IL270596B2
(en)
|
2017-05-25 |
2026-01-01 |
Bristol Myers Squibb Co |
Antibodies containing heavy constant regions are adapted for use in cancer therapy
|
|
WO2018217976A1
(en)
|
2017-05-25 |
2018-11-29 |
Bristol-Myers Squibb Company |
Antagonistic cd40 monoclonal antibodies and uses thereof
|
|
AU2018361743A1
(en)
|
2017-11-03 |
2020-04-09 |
Novartis Ag |
Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
|
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
AR117091A1
(es)
*
|
2018-11-19 |
2021-07-07 |
Bristol Myers Squibb Co |
Anticuerpos monoclonales antagonistas contra cd40 y sus usos
|
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|